|Bid||46.24 x 800|
|Ask||46.25 x 2900|
|Day's Range||46.17 - 47.87|
|52 Week Range||33.51 - 67.85|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.71|
FibroGen, Inc. (NASDAQ:FGEN) shareholders might be concerned after seeing the share price drop 15% in the last...
SAN FRANCISCO, June 28, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial.
FibroGen Inc NASDAQ/NGS:FGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for FGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 11. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding FGEN are favorable, with net inflows of $2.57 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by nearly 9 percentage points since the end of the third quarter of 2018 as investors worried over the possible ramifications of rising interest rates and escalation of the trade war with China. The hedge funds and institutional investors we track typically invest more […]
Every investor in FibroGen, Inc. (NASDAQ:FGEN) should be aware of the most powerful shareholder groups. Generally...
SAN FRANCISCO, June 10, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today.
“Suzanne Blaug joins the FibroGen Board of Directors at a key time for the company. “I am excited to join FibroGen's Board as the company prepares for critical next steps in the regulatory and commercial development of roxadustat for the treatment of anemia associated with CKD and in other important applications in the treatment of anemia.
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") ...
FibroGen news has FGEN stock down on Friday after releasing confusing results from a recent trial.Source: Shutterstock The report from FibroGen (NASDAQ:FGEN) has to do with its Roxadustat drug for treating kidney disease. The statements made by the company in this update weren't exactly clear. This includes "we believe there is no clinically meaningful difference in risk."These unclear statements from the company were able to give some investors doubts about the drug. However, it looks like the results are better than expected. It was just the wording in the FibroGen news release that was causing problems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"There is confusion in the market currently, but this should become clear as more investors realize the data is positive and Roxa's risk/benefit is favorable, so we see the stock rebounding and moving back up over time," Jefferies analysts said in a statement obtained by FierceBiotech.The FibroGen news about Roxadustat comes in the company's earnings report for the first quarter of 2019. The poor wording and confusion was also dragging down an otherwise solid earnings report. * 7 Cloud Stocks to Buy on Overcast Days FibroGen reported losses per share of 53 cents on revenue of $23.86 million. Losses per share and revenue from the same time last year were 50 cents and $31.93 million. Wall Street was looking for the company to reported losses per share of 67 cents on revenue of $20.00 million.FGEN stock was down 24% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Cloud Stocks to Buy on Overcast Days * 6 Stable Stocks Worth Buying for Protection * 5 Active Vanguard Funds That You Have to Own As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post FibroGen News: Why FGEN Stock Is Plummeting Today appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 9) Alcon AG (NYSE: ALC ) ANI Pharmaceuticals Inc (NASDAQ: ...
FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Francisco-based company said it had a loss of 53 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Positive topline results from pooled safety analyses of roxadustat Phase 3 global programCompleted one year of treatment in Phase 2 trial evaluating pamrevlumab in treatment of.
FibroGen, Inc. (FGEN) today announced topline results from the pooled safety analyses of the global Phase 3 program for roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI). The global pivotal Phase 3 trials were conducted by FibroGen and collaboration partners AstraZeneca and Astellas Pharma, Inc., for treatment of anemia in chronic kidney disease (CKD) patients across the non-dialysis-dependent (NDD), incident (newly initiated) dialysis, and dialysis-dependent (DD) CKD populations, enrolled from more than 50 countries.
SAN FRANCISCO, May 06, 2019 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019 after market.
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in FibroGen, Inc. (NASDAQ:FGEN) then it's worth thinking about how it contributes t...